Studies on inclusion complexes of 2-[Substituted arylideamino]-1, 3, 4-thiadiazino [6,5b]indole with β- Cyclodextrin

Journal of the Iranian Chemical Research

مقاله 8، دوره 5، شماره 2، شهریور 2012، صفحه 119-128   

نویسندگان

Sunakar Panda^* ؛ Jagat Krushna Tripathy

Department of Chemistry Berhampur University, Bhanja Bihar, Odisha, India

چکیده

Inclusion complexes of 2-[Arylidenamino]-1,3,4-thiadiazino[6,5b]indoles have been prepared with β-
cyclodextrin so as to increase the solubility of these compounds in polar medium which may increase their
bioaccessibility. The formation of inclusion complexes is known from the study of changes in physical and
spectral properties of the compounds. The stability of the inclusion complexes has been studied by the
determination of the thermodynamic parameters like change in free energy, change in enthalpy and change in
entropy. Finally compounds and their inclusion complexes are screened for antibacterial and antioxidant
activities. It is found that both antibacterial and antioxidant activity of the compounds increase significantly
after the inclusion complex formation. In addition, the presence of activating groups on arylidene unit further
favours inclusion complex formation and also stabilizes the same.

کلیدواژه‌ها

Substituted indole؛ β Cyclodextrin؛ Inclusion complex؛ Antimicrobial Activity؛ Antioxidant activity

مراجع

[1] A.K. Sengupta, A K. Pandey, H.N. Verma, M.W.A Ali Khan, J. Ind. Chem. Soc. 62 (1985) 165-169.
[2] R. Patil, J S Biradar, Ind. J.Pharm. Sc. 63 (2001) 299-305.
[3] M.V. Shetty, P Parimo, Y. M. Chopra, Eur. J. Med. Chem. (1978) 581-584.
[4] H. Inlon, H Vogelaer, M. De Descamps, J Bauthier, M Colot, J Richard, R Charlier, Chem. Abst., Am.
Chem. Soc. 88 (1978) 601-604.
[5] M. Oimoni, M. Hamada, T. Hava, J Ant. Japan. 27 (1974) 989-990.
[6] B.S. Holla, K V Udupa, J. Ind. Chem. Soc. 65 (1988) 524-525.
[7] S. Kapimoto, J Nishie, Jap. J. Tub. 2 (1954) 334-336.
[8] H. Panwar, R.S Verma, V.K Srivastava, Ashok Kumar, Ind. J. Chem. 45B (2006) 2099-2104.
[9] B.Pose-Vilarnovo, I.Predomo-Lopez , M Echezarreta-Lopez., J. Pharm. Sci.. 13 (2001) 325-331.
[10] V.G Belikov, E.V. Komapantseva, Khim. Farm. Zh. 24 (1990) 19-43.
[11] H. Yano, F. Hiramaya, H. Arima, J. Pharm. Sci. 90 (2001) 493-503.
[12] C.F.H. Allen, G.H.W. Mekee, Organic Synthesis, Coll. 1965-2005.
[13] T.Higuchi, K. Connors, Adv. Anal. Chem. Inst. 4 (1965) 117-212.
[14] S. Panda, S.S. Nayak, Asian J. Res. Chem. 2 (2009) 539-543.
[15] H.A. Benesi, J.H. Hilderband, J. Am. Chem. Soc. 71 (1999) 2703-2707.
[16] V.R. Bollela, D.N. Sato, B.A.L. Fonesca, Braz. J. Med. Biol. Res. 9 (1999) 32-38.
[17] R.Cruickshank, J.P. Marmion, R.H.A. Swain, J.Med. Microb. 11 (1975) 91-95.
[18] M Tagashira, Y. Ohtake, J. Plant. Med. 64 (1998) 555-558.
[19] K.G. Mohammed, C.A Moji, Pharm. Dev. Tech. London. 6 (2001) 315-324.
[20] S.S. Nayak, S. Panda, P. Panda, M.S. Padhy, Bul. Chem. Comm. 42 (2010) 147-151.
[21] A.P Mukna, M.S. Nagarsenkar, Am. Asso. Pharm. Sci. Pharm. Sci. Tech. 5 (2001) 19-23.
[22] Z. Szetli, Controlled Drug Bio-availability, Willey Inter Science, New York, 1985.
[23] S.Tommasini, D. Raneri, R. Ficarra, M.L. Calabro, R. Stancanelli, J. Pharm. Biomed. Anal. 35 (2004)
379-387.
[24] R.A Rajewski, V.J.Stella, J. Pharm.Sci. 85 (1996) 1142-1169.
[25] Y.L. Loukas, V.Vraka, G Gregordias, J. Pharm. Biomed. Anal. 16 (1997) 263-268.
S. Panda & J.K. Tripathy, J. Iranian Chem. Res. 5 (2) (2012) 119-128
128
[26] T. Stalin, P Vasantharani, B. Shanti, A. Sekhar, N Rajendra., Ind. J. Chem. Sec A. 45 (2006) 1113-
1120.
[27] A.V. Astakhova , N.Demina, J. Pharm.Chem. 38 (2004) 105-108.